These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6109889)

  • 1. Iron chelation in red cell ghosts.
    Smith GN
    Lancet; 1981 Jan; 1(8213):222-3. PubMed ID: 6109889
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation in red cell ghosts.
    Smith GN
    Lancet; 1980 Dec 20-27; 2(8208-8209):1363. PubMed ID: 6109171
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
    Green R; Miller J; Crosby W
    Blood; 1981 May; 57(5):866-72. PubMed ID: 7214016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.
    Cohen A; Schwartz E
    Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 7. Red cell ghost-entrapped deferoxamine as a model clinical targeted delivery system for iron chelators and other compounds.
    Green R
    Bibl Haematol; 1985; (51):25-35. PubMed ID: 4004761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial of desferrioxamine entrapped in red cell ghosts.
    Green R; Lamon J; Curran D
    Lancet; 1980 Aug; 2(8190):327-30. PubMed ID: 6105474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current recommendations for chelation for transfusion-dependent thalassemia.
    Kwiatkowski JL
    Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial retrospective. Iron loading in thalassemia--five years with the pump.
    Weatherall DJ; Pippard MJ; Callender ST
    N Engl J Med; 1983 Feb; 308(8):456-8. PubMed ID: 6823257
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 14. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

  • 20. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C; Lagos P; Langona E
    Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.